| | | | Sounds eerlily familiar, as in IMMU, except that IBRX already has one approved indication. No doubt the owner and Sr. mgmt leave much to be desired. Institutional ownership, until recently, has had very little holdings in IBRX, probably because Patrick holds soo much and shares soo little. I do think that the recent stakeholders will "shake the tree" pretty hard, going forward. I'm expecting more news on those fronts and other fronts, soon. Downside seems much less than upside, going forward, IMO, which is the reason I'm adding more. That, and my basis continues to fall, just like a knife, come to think of it. Ha Ha. |
|
